Skip to main content

4 Result(s)

within Thomas Decaens Remove this filter Biomedicine Remove this filter

and

  1. Article

    Open Access

    Plasma ALS and Gal-3BP differentiate early from advanced liver fibrosis in MASLD patients

    Metabolic dysfunction-associated steatotic liver disease (MASLD) is estimated to affect 30% of the world’s population, and its prevalence is increasing in line with obesity. Liver fibrosis is closely related t...

    David Pérez Compte, Lucas Etourneau, Anne-Marie Hesse… in Biomarker Research (2024)

    Download PDF (2268 KB) View Article

  2. Article

    Open Access

    Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression

    Thomas Decaens, Carlo Barone, Eric Assenat, Martin Wermke… in British Journal of Cancer (2021)

    Download PDF (222 KB) View Article

  3. Article

    Open Access

    Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression

    This Phase 1b/2 study evaluated tepotinib, a highly selective MET inhibitor, in US/European patients with sorafenib pretreated advanced hepatocellular carcinoma (aHCC) with MET overexpression.

    Thomas Decaens, Carlo Barone, Eric Assenat, Martin Wermke… in British Journal of Cancer (2021)

    Download PDF (465 KB) View Article

  4. No Access

    Chapter

    mTOR and Cancer Therapy: Clinical Development and Novel Prospects

    mTOR, a pivotal signal transduction protein involved in multiple cellular functions in tumors at the level of cancer and stroma cells, represents an attractive target for cancer therapy. Rapamycin and several ...

    Sandrine Faivre, Thomas Decaens… in mTOR Pathway and mTOR Inhibitors in Cancer… (2010)